COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Issues EUA for Third Diagnostic SARS-CoV-2 POC Antigen Test

FDA maze of regulations
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

As antigen-based COVID-19 testing becomes more prevalent, a third test and EUA may mark another breakthrough, adding momentum for wider use of rapid point-of-care coronavirus diagnostic testing.

The US Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for a third SARS-CoV-2 antigen-based diagnostic test. This EUA was granted on Aug. 18, 2020, and was granted to LumiraDx for their LumiraDx SARS-CoV-2 Ag Test.

This new EUA is similar to the previous two COVID-19 antigen EUAs in that it permits point-of-care (POC) applications of the test and requires that it be used in clinical settings under Clinical Laboratory Improvement Amendments (CLIA) Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Previously, the FDA had granted EUAs for POC SARS-CoV-2 antigen tests to Quidel and Becton Dickinson. Use of these tests has quickly become prominent, with several federal and state-level funding initiatives and purchase commitments. 

FDA Commissioner Stephen M. Hahn, MD, has promoted antigen COVID-19 tests, saying, “Antigen tests play an important role in the overall response against COVID-19, including as a point-of-care test that can potentially scale up to test millions of Americans quickly.”

Related Resources:

LumiraDx UK Ltd. EUA Letter

Quidel EUA Letter

Becton Dickinson EUA Letter

COVID-19 TESTING DATA

Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.

Sincerely,

Robert L. Michel
President, Founder
The Dark Intelligence Group